LONDON -- Management can make all the difference to a company's success and, thus, its share price.
The best companies are those run by talented and experienced leaders with strong vested interests in the success of the business, held in check by a board with sound financial and business acumen. Some of the worst investments to hold are those run by executives collecting fat rewards as the underlying business goes to pot.
In this series, I'm assessing the boardrooms of companies within the FTSE 100. I hope to separate the management teams that are worth following from those that are not. Today, I am looking at�Compass Group� (LSE: CPG ) , the world's largest contract caterer.
Here are the key directors:
Director
Position
Sir Roy Gardner
Chairman
Richard Cousins
Chief Executive
5 Best Gold Stocks To Buy For 2015: Remy International Inc (REMY)
Remy International, Inc. (Remy), incorporated on November 22, 1993, is a global vehicular parts designer, manufacturer, remanufacturer, marketer and distributor of aftermarket and original equipment electrical components for automobiles, light trucks, heavy-duty trucks and other vehicles. Remy sells its products worldwide primarily under the Delco Remy, Remy, and World Wide Automotive brand names. The Company�� products include light-duty and heavy-duty starters and alternators for both the original equipment and the remanufactured markets, and hybrid power technology. These products are principally sold or distributed to original equipment manufacturers (OEMs) for both original equipment manufacture and aftermarket operations, as well as to warehouse distributors and retail automotive parts chains. The Company sells its products principally in North America, Europe, Latin America and Asia-Pacific. In January 2014, Remy International, Inc. acquired all assets of USA Industries.
The Company�� original equipment division consists of three primary channels: automotive, heavy-duty vehicles and electric motors for electric and hybrid applications. Remy is a supplier for such original equipment manufacturers as General Motors, DaimlerChrylser, Toyota, Honda and Hyundai/Kia. The Company is a supplier of original equipment and aftermarket starters and alternators for heavy-duty vehicles in North America. Remy is an independent production electric motor supplier and in many aspects of hybrid and electric vehicle technology, including the patented hairpin stator technology. Its original equipment (OE) business has operations in the United States, Mexico, Brazil, China and Korea.
Advisors' Opinion:- [By Rich Smith]
On Monday, auto parts maker Remy International (NASDAQ: REMY ) announced that it is taking 100% control of its Remy Hubei Electric Co. (REH) joint venture, buying out partner Hubei Super Electric Auto Motor Company's 49% interest in the JV.
5 Best Industrial Disributor Stocks To Invest In Right Now: C.R. Bard Inc. (BCR)
C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular, urology, oncology, and surgical specialty products. The company?s vascular products include percutaneous transluminal angioplasty catheters, chronic total occlusions catheters, guidewires, introducers, and accessories; peripheral vascular stents and stent grafts, vena cava filters, and biopsy devices; electrophysiology products, such as electrophysiology laboratory systems and diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. Its urology products comprise infection control Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachyt herapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for ureteroscopic procedures and stone removal; and catheter stabilization devices. The company?s oncology products consist of specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation systems for hernia and other soft tissue repairs; irrigation devices for orthopedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. C. R. Bard sells its products directly and through distributors to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company was founded in 1907 and is based in Murray Hill, New Jersey.
Advisors' Opinion:- [By Ben Levisohn]
Intuitive Surgical has gained 4.3% to $397.20 today, easily trumping the gains in other healthcare-equipment companies. �Covidien�(COV) has ticked down 0.3% to $60.08, Medtronic�(MDT) has gained 0.5% to $52.97, Abbott Laboratories�(ABT) has fallen 0.8% to $33.24, and C.R. Bard (BCR) is little changed at $114.52.
5 Best Industrial Disributor Stocks To Invest In Right Now: Opus International Consultants Ltd (OIC)
Opus International Consultants Limited is a supplier of multidisciplinary consultancy and project management services across a range of disciplines including, civil, mechanical and electrical engineering, and planning, environmental, architectural and property management. The Company operates in four segments: New Zealand, United Kingdom, Australia and Canada. Services supplied support asset development and asset management activities of the Company�� clients. Asset management services include property management and asset maintenance services predominantly using our engineering and environmental specialists. Asset development services include civil, mechanical and electrical engineering, planning, environmental and architectural work. Effective September 3, 2013, Opus International Consultants Ltda majority-owned unit of Opus Group Bhd acquired Stewart, Weir & Co Ltd. Advisors' Opinion:- [By John McCamant]
Nektar Therapeutics (NKTR) is expected to get FDA approval this year for its lead drug naloxegol, a once-a-day pill for opioid-induced constipation (OIC). The drug is licensed to AstraZeneca. NKTR will receive up to $245 million in milestone payments, plus royalties.
5 Best Industrial Disributor Stocks To Invest In Right Now: Charles River Laboratories International Inc. (CRL)
Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Advisors' Opinion:- [By Damian Illia]
Based in Valencia, Calif., and founded in 1991, MannKind Corporation (MNKD) is a development stage biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapeutic products for diseases like diabetes. The company's lead and only late stage pipeline candidate for this year is Afrezza, an inhalation powder which is an ultra insulin therapy for the treatment of adults with type 1 or type 2 diabetes to control their hyperglycemia. Currently, it is in late-stage clinical trials and a final decision from the U.S. regulatory body is expected by April 15, 2014. There is great concern revolving around this decision, as MannKind has already received two complete response letters (CRL) for Afrezza from the FDA, and it was requested to conduct two phase III trials with the next-generation inhaler. Further delay in approval or another setback related to this candidate could be a great danger for the company. Over and probably excessive dependence on Afrezza ���s the company discontinued any other reasearch in other candidates ���s something to worry about. The company has generated no revenue last year round and its shares have experienced a total annual loss of $0.64 so far.
No comments:
Post a Comment